If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. A webcast of the presentation can be accessed here or under “News & Events” in the Investor Relatio ...

WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m. E.T. on Tuesday, February 11, 2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q ...

WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors section of t ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 2:40 p.m. ET.The live event and replay of the presentation will be available under "Events and Presenta ...

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.   A webcast of Sensei’s presentation will be available in the Investor ...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025. Details are as follows: Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceConference Date: February 11-12, 202 ...

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 04, 2025 7:27 AM EST | Source: Cardiol Therapeutics Inc.Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that ...

Exhibit 99.1 Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings New York, January 31, 2025 – Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for liability-based awards totaling $20.5 million and $32.6 million, respectively, ...